Divestitures Still Possibile as Beckman Coulter Wraps Up Restructuring; Sales Force Reorganized | GenomeWeb

As Beckman Coulter nears the end of its reorganization, begun last summer, the firm is still considering divesting some "minor" product lines or other assets.

"The situation hasn't changed from the original announcement," said Paul Whitlock, a Beckman Coulter spokesperson. "We haven't actually done anything yet, but we continue to investigate those possibilities."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.